|Home||Internet of Things||Aerospace||Apparel||Energy||Defense||Health Care||Logistics||Manufacturing||Retail|
RFID News Roundup
GuardRFID unveils proximity tag exciter for room- or bed-level location ••• Bluewater Health selects Awarepoint RTLS ••• Texas A&M picks Apptricity RFID solution to manage Corps of Cadets uniforms ••• Norway Post expands implementation of Nedap's multi-access RFID solution ••• Thinfilm, Ypsomed partner on NFC-enabled injection systems for self-medication ••• Fujitsu outfits work van with RFID, GPS, sensors and more.
Thinfilm, Ypsomed Partner on NFC-enabled Injection Systems for Self-Medication
Thin Film Electronics (Thinfilm), a Norwegian provider of printed electronics and smart systems, and the Ypsomed Group, a developer and manufacturer of injection systems for self-medication, have announced a partnership to incorporate Thinfilm's Near Field Communication (NFC) OpenSense technology in the YpsoMate autoinjector as a means of improving patient self-care compliance.
YpsoMate autoinjectors are disposable two-step injection systems that house prefilled glass or polymer syringes, Thinfilm reports, and are triggered by push-on-skin activation. Patients use autoinjectors to self-deliver periodic injections for the ongoing management of chronic conditions, such as rheumatoid arthritis or cardiovascular indications, making compliance a critical factor in their treatment plan.
According to Thinfilm, NFC OpenSense tags are thin, flexible labels that can detect both the state before and after injection of an YpsoMate Smart autoinjector, as well as wirelessly deliver medication to patients through the simple tap of a smartphone, and record patients' interactions with the YpsoMate Smart device in the cloud. Each tag contains a unique identifier that makes it possible to track every YpsoMate Smart autoinjector to the individual item level. In addition, Thinfilm reports, the tag remains active even after the factory seal has been broken, enabling an extended dialogue between patients, doctors and brands.
Ypsomed will invest more than 50 million Swiss francs (approximately $50 million) during the coming years in the research and development of the new generation of injection and infusion systems. These systems support the administration of medications with intelligent electronic and software-based additional functions. Commercial availability of the systems has not yet been determined.
Login and post your comment!
Not a member?
Signup for an account now to access all of the features of RFIDJournal.com!
SEND IT YOUR WAY
RFID JOURNAL EVENTS
ASK THE EXPERTS
Simply enter a question for our experts.
TAKE THE POLL
|RFID Journal LIVE!||RFID in Health Care||LIVE! LatAm||LIVE! Brasil||LIVE! Europe||RFID Connect||Virtual Events||RFID Journal Awards||Webinars||Presentations|